Bridging the Gap to Reach Treatment Goals in DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment.

 

This activity is supported through educational grants from Kite.

Click here to access content.

Target Audience

This activity is intended for hematologic oncology clinicians (physicians, physician associates, nurses, pharmacists) who provide care for individuals with aggressive B-cell lymphomas who may be candidates for cellular therapy.

Learning Objectives

After completing this CE activity, the participant should be better able to:

  • Assess the efficacy and safety of current and emerging therapeutic options for the treatment of R/R DLBCL
  • Evaluate the potential use of bridging therapies in patients with R/R DLBCL if the therapy goal is CAR T or stem cell transplant
  • Plan strategies to overcome barriers in accessing care and involvement in clinical trials for patients with DLBCL
Additional information

Contact

Name: 
Sherry Fisher
Phone Number: 
+1 (414) 805-0689
Email: 
[email protected]
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
02/05/2023
Course expires: 
02/05/2024
Cost:
$0.00

Christopher R. Flowers, MD, MS, FASCO

Division Head ad Interim, Division of Cancer Medicine 

Department Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine

MD Anderson Cancer Center

Houston, TX

Sergio A. Giralt, MD, FACP

Melvin Berlin Family Chair in Myeloma Research

Professor of Medicine

Weill Cornell Medical College

Deputy Head, Division of Hematologic Malignancies

Attending Physician, Adult BMT Service

Memorial Sloan Kettering Cancer Center

New York, NY

Sanjay K. Juneja, MD

Hematology, Medical Oncology

Chief of Oncology Line

Baton Rouge General Hospital

Mary Bird Perkins Cancer Center

Baton Rouge, LA

Sanjay Sharma, MD

St. Jude Crosson Cancer Institute

Providence OC Cancer Institute

Fullerton, CA

Special Video Appearance by:

Rayne H. Rouce, MD, BS

Associate Professor

Department of Pediatrics

Texas Children's Cancer Center for Cell and Gene Therapy

Baylor College of Medicine

Houston, TX

Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
 
This activity is co-provided with our educational partner, Medicial Learning Institute Inc.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.